TAK-279 placebo (same excipient as TAK-279)
Sponsors
Takeda Development Center Americas Inc.
Conditions
Moderate to Severe Plaque PsoriasisModerate to Severely Active Ulcerative ColitisModerately to Severely Active Crohn's Disease
Phase 2
A Phase 2b, Multicenter, Randomized, Double-blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease
RecruitingCTIS2023-506704-14-00
Start: 2024-09-04Target: 127Updated: 2025-12-12
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis
RecruitingCTIS2023-506769-67-00
Start: 2024-09-04Target: 139Updated: 2025-12-01
Phase 3
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
CompletedCTIS2023-505842-24-00
Start: 2024-05-07End: 2025-10-24Target: 686Updated: 2025-12-16
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis
CompletedCTIS2023-505841-22-00
Start: 2024-04-04End: 2025-10-09Target: 235Updated: 2025-12-10